Read this company snapshot
Daily valuation snapshot
uniQure N.V.: source evidence dated 2026-10-09.
- Daily close (USD)
- $22.59
- Market capitalization (USD)
- $1,566,274,013.01
- Price / earnings (TTM)
- Not reported
- Price / book
- 4.83
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research QURE in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research QURE in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing QURE with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $22.59 |
| Market capitalization (USD) | $1,566,274,013.01 |
| Price / earnings (TTM) | Not reported |
| Price / book | 4.83 |
No matching rows. Clear the filter to see all records.
Read QURE's valuation metrics
Company size
uniQure N.V.'s recorded market capitalization is $1,566,274,013.01. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
QURE's recorded price-to-book ratio is 4.83. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research uniQure N.V. with Aurora
Use the snapshot above to ask a specific question about QURE. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow QURE's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.